Abstract | BACKGROUND: OBJECTIVES: SEARCH STRATEGY: The MEDLINE, PUBMED and EMBASE databases were searched using the search criteria " microscopic colitis" or " lymphocytic colitis" and "treatment" or " therapy" or "management" to identify relevant papers published between 1970 and September 2006. Manual searches from the references of identified papers and relevant review papers were performed. Abstracts from major gastroenterological meetings were searched to identify research submitted in abstract form only. Finally, the Cochrane Central Register of Controlled Trials and the Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group Specialized Trials Register was searched for other studies. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Data were extracted independently by each author onto 2x2 tables (treatment versus placebo and response versus no response). For therapies assessed in one trial only, P values were derived using the chi-square test. MAIN RESULTS: There were 5 patients with lymphocytic colitis in the trial studying bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks vs. placebo). Although all three patients on active drug experienced clinical improvement compared to none of the placebo group, there were no statistically significant differences in clinical (P = 0.10) or histological (P = 0.71) improvement. AUTHORS' CONCLUSIONS:
|
Authors | N Chande, J W D McDonald, J K Macdonald |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 1
Pg. CD006096
(Jan 24 2007)
ISSN: 1469-493X [Electronic] England |
PMID | 17253579
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Antidiarrheals
- Organometallic Compounds
- Salicylates
- bismuth subsalicylate
- Bismuth
|
Topics |
- Antidiarrheals
(therapeutic use)
- Bismuth
(therapeutic use)
- Colitis, Lymphocytic
(drug therapy)
- Humans
- Organometallic Compounds
(therapeutic use)
- Salicylates
(therapeutic use)
|